Corient Private Wealth LLC Purchases 190 Shares of argenx SE (NASDAQ:ARGX)

Corient Private Wealth LLC increased its holdings in argenx SE (NASDAQ:ARGX) by 14.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,485 shares of the company’s stock after purchasing an additional 190 shares during the period. Corient Private Wealth LLC’s holdings in argenx were worth $913,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Envestnet Portfolio Solutions Inc. raised its position in shares of argenx by 7.9% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,509 shares of the company’s stock valued at $928,000 after buying an additional 111 shares in the last quarter. Natixis Advisors LLC increased its stake in argenx by 32.5% during the fourth quarter. Natixis Advisors LLC now owns 15,923 shares of the company’s stock worth $9,793,000 after acquiring an additional 3,909 shares during the last quarter. Aviso Financial Inc. purchased a new stake in argenx during the fourth quarter valued at approximately $180,000. ANTIPODES PARTNERS Ltd lifted its stake in shares of argenx by 114.8% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 116 shares of the company’s stock valued at $71,000 after purchasing an additional 62 shares during the last quarter. Finally, Avantax Advisory Services Inc. boosted its holdings in shares of argenx by 15.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 1,061 shares of the company’s stock worth $653,000 after purchasing an additional 139 shares during the period. Institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on ARGX shares. Robert W. Baird raised their price target on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 4th. William Blair restated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Citigroup reiterated an “outperform” rating on shares of argenx in a report on Friday, February 28th. Wedbush reissued an “outperform” rating and issued a $655.00 price objective on shares of argenx in a research note on Tuesday, December 3rd. Finally, Piper Sandler upped their target price on argenx from $620.00 to $725.00 and gave the company an “overweight” rating in a research note on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, argenx has an average rating of “Moderate Buy” and a consensus price target of $687.00.

argenx Stock Up 1.7 %

Shares of ARGX stock opened at $593.47 on Friday. The company’s 50 day moving average is $629.28 and its 200 day moving average is $600.95. The firm has a market cap of $36.06 billion, a price-to-earnings ratio of -674.40 and a beta of 0.59. argenx SE has a 52-week low of $352.77 and a 52-week high of $678.21.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.